Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FasNaGel

Financiado

Cerrado

NOVEL THERAPEUTIC NANOHYDROGEL FOR ACUTE AND CHRONIC PAIN TREATMENT TARGETED TO...

NOVEL THERAPEUTIC NANOHYDROGEL FOR ACUTE AND CHRONIC PAIN TREATMENT TARGETED TO THE NERVES FASCIA Worldwide chronic pain conditions are by far the greatest cause of disability. It has an enormous negative impact on quality of life and on personal and professional plane. Chronic pain is an important cause of depression, more si... ver más

30/11/2018

I+MED S.COOP. PEQU...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

I+MED S.COOP. PEQUEÑA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 50K€

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 5 años

0% 70% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

I+MED S.COOP. PEQUEÑA

50.00K€ | Lider

AB AZUCARERA IBERIA

250.84K€ | Participante

VALORIZACIONES ORGANICAS AGR...

205.89K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2018-05-07
Fecha Fin: 2018-11-30

Líder del proyecto

I+MED S.COOP. PEQUEÑA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 50K€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Worldwide chronic pain conditions are by far the greatest cause of disability. It has an enormous negative impact on quality of life and on personal and professional plane. Chronic pain is an important cause of depression, more sickness absences at work, productivity losses, unemployment, etc.). Chronic pain is one of the major reasons (30%) why people exit the labour market prematurely. 20% of current population in Europe suffers from chronic pain (102 mill.) and up to 50 % of that pain comes from wrongly treated acute post-operative pain. The total direct and indirect healthcare costs for chronic pain disorders in Member States have an EU average of 2.4 % of GDP and a cost of 271 billion euros per year. When acute pain is not properly treated in the first few days, it can become chronic. About 40-60% of patients report pain chronification after surgery. Current medicines do not prevent chronic pain from the start and have side effects. Fast track approaches have started to take the lead in pain management policies. Based on these approaches I +Med´s team works since 2014 in the development of FasNaGel, a new nanomedicinal product, unique in the world. It consists of a biocompatible and biodegradable injectable carrier, made of porous nanostructured hyaluronic acid hydrogel containing a non-steroidal anti-inflammatory drug that i) efficiently, provides a 100% of functional recovery after surgery in one third of the time, ii) is easy-to-use by medical staff, and the most important iii) increases by 80% the treatment effectiveness. FasNaGel will reduce the overall treatment costs in Europe, deducting indirect costs coming from acute pain up to €149 billion. The objective of this proposal is to be able to perform a thorough feasibility study for the validation of the production and commercialization of this novel product. FasNaGel marketing will have a huge of a SME such as i+Med, who estimates to multiply the team size by 8 in 7 years.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores